Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
5.34 ^USD	-8.09%		-0.56%	+3.49%

14/05	Transcript : Sight Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:15 AM
03/05	Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed	MT

Sight Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 08, 2024 at 02:35 am IST

Sight Sciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 81.06 million compared to USD 71.33 million a year ago. Net loss was USD 55.55 million compared to USD 86.24 million a year ago.

Basic loss per share from continuing operations was USD 1.14 compared to USD 1.8 a year ago.

Latest news about Sight Sciences, Inc.

Transcript : Sight Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:15 AM	14/05
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed	03/05	MT
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, vs. Street Est of $18.4M	03/05	MT
Transcript : Sight Sciences, Inc., Q1 2024 Earnings Call, May 02, 2024	03/05
Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024	03/05	CI
Sight Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Sector Update: Health Care Stocks Edge Higher Late Afternoon	30/04	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	29/04	MT
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump	29/04	MT
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump	29/04	MT
Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study	11/04	CI
Sector Update: Health Care Stocks Flat Pre-Bell Wednesday	03/04	MT
Sight Sciences to Present Data From Studies of Glaucoma, Dry Eye Technologies -- Shares Extend Gains to Premarket	03/04	MT
Sight Sciences to Present Data From Studies of Glaucoma, Dry Eye Technologies -- Shares Jump After Hours	03/04	MT
Sight Sciences, Inc. Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT At the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	03/04	CI
Stifel Adjusts Price Target on Sight Sciences to $7 From $6, Keeps Buy Rating	08/03	MT
Transcript : Sight Sciences, Inc., Q4 2023 Earnings Call, Mar 07, 2024	08/03
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q4 Revenue $18.8M, vs. Street Est of $19.4M	08/03	MT
Sight Sciences, Inc. Provides Earnings Guidance for the Year 2024	08/03	CI
Sight Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
Sight Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/03	CI
Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting	15/02	CI
Sight Sciences Announces the Closing of Up to $65 Million Senior Secured Credit Facility with Hercules Capital	24/01	CI
Sight Sciences, Inc. announced that it expects to receive $65 million in funding	22/01	CI
Sight Sciences Expects Lower Q4, Higher Full-Year 2023 Revenue	09/01	MT

Chart Sight Sciences, Inc.

Duration

Period

More charts

Company Profile

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.

Sector

Medical Equipment, Supplies & Distribution

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Sight Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.34 USD

Average target price

6.1 USD

Spread / Average Target

+14.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SIGHT SCIENCES, INC.	+3.49%	266M
ABBOTT LABORATORIES	-5.43%	181B
MEDTRONIC PLC	+4.30%	114B
BECTON, DICKINSON AND COMPANY	-3.09%	68.29B
DEXCOM, INC.	+5.86%	52.24B
CENCORA, INC.	+8.15%	44.3B
HOYA CORPORATION	+7.52%	42.73B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	32.52B
TERUMO CORPORATION	+17.85%	26.02B
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	25.91B

Other Medical Equipment, Supplies & Distribution